COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND 3RD GENERATION EGFR TYROSINE KINASE INHIBITORS
Application
US20260078191A1
Kind: A1
Mar 19, 2026
Inventors
Sylvie LAQUERRE, Matthew LORENZI, Sheri MOORES
Abstract
The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors.
CPC Classifications
C07K 16/2863
A61K 31/5377
A61K 39/39558
A61P 35/00
A61K 2039/505
C07K 2317/31
C07K 2317/51
C07K 2317/515
C07K 2317/56
C07K 2317/565
Filing Date
2025-09-24
Application No.
19338193